Protagonist Therapeutics, Inc (PTGX)

Every figure this model derived for PTGX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 615,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 782,576,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 807,148,000 AssetsCurrent 2026-06-30
current liabilities 37,181,000 LiabilitiesCurrent 2026-06-30
equity 841,543,000 StockholdersEquity 2026-06-30
ocf 131,197,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 269,843,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 49,816,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PTGX on one particular measure came for.

RatioValue
cash operating margin40.65
current ratio21.71
current ratio reported21.71
dilution pct-2.31
ebit yoy143.34
fcf margin48.39
growth cv1.96
operating margin21.62
owner earnings margin29.93
revenue growth696.77
revenue growth per share715.64
rpo growth-15.23
rule of 40718.39
sbc pct revenue18.46

What to be careful about

What this model itself distrusts about PTGX's figures. Written by the derivation as it ran, not added afterwards.